9 min read
Monthly FDA Guidance and Regulatory News Review - March 2026
March 2026 regulatory updates underscore newly published final and draft guidances focused on real-world data, safety...
Veristat offers superior expertise to overcome cancer clinical development challenges – planning and mitigating risks throughout oncology clinical trial design and execution is at the core of what we do.
Our experienced teams have helped sponsors with more than 390 oncology studies for solid tumors, hematologic malignancies, and diagnostic imaging tools. Additionally, we’ve prepared more than 30 marketing applications that were successfully submitted to the US Food & Drug Administration (FDA) and the European Medicines Agency (EMA) for cancer treatments, including many rare cancers.
We have a wide range of cancer clinical experience, from trial design to patient recruitment and site engagement to submission. We would love the opportunity to help you with your current or next cancer trial.
To speak with our experts at ASCO, fill out the form on the right side of this page. Learn how we can help you advance your next cancer clinical trial or program to successful operational outcomes.
Cancer clinical trials are highly complex, take longer to run and are the costliest types. Veristat will advance your cancer therapy through all phases of clinical development through to market launch and beyond - Contact us or explore more of our insights and experience running cancer programs:
9 min read
Apr 6, 2026 Veristat Blog
March 2026 regulatory updates underscore newly published final and draft guidances focused on real-world data, safety...
7 min read
Mar 27, 2026 Veristat Blog
In February 2026, FDA activity included new draft guidances, regulatory initiatives (e.g., PreCheck and eCTD 4.0),...